Layer 05 · Economics
Study / economics
Per-study revenue assumptions used by Forecasting, Invoice Readiness, and Pharma Watcher. TA × Phase defaults pre-fill new entries but every study can override them.
Studies on file
6
4 active · 1 pipeline
Awarded
1
0 closed · 0 declined
Total gross potential
$2.91M
all statuses
Probability-weighted
$2.78M
risk-adjusted total
Studies · 6 of 6
| Protocol | Sponsor · CRO | TA · Phase | Status | P(award) | Gross | P-Wtd | |
|---|---|---|---|---|---|---|---|
ONCO-241 Pembrolizumab Combo · Adv NSCLC | Pfizer Parexel | Oncology Phase III | Active | 100% | $859K | $859K | |
CARDIO-118 Heart Failure Antifibrotic · HFrEF | AstraZeneca ICON | Cardiology Phase II | Active | 100% | $376K | $376K | |
NEURO-077 Anti-Tau · Early Alzheimer's | Eli Lilly IQVIA | Neurology Phase II | Active | 100% | $412K | $412K | |
DERM-302 Topical JAKi · Atopic Dermatitis | Eli Lilly Syneos | Dermatology Phase III | Awarded | 100% | $541K | $541K | |
GI-211 IL-23 Inhibitor · Crohn's Disease | BMS Labcorp | Immunology Phase II | Pipeline | 65% | $394K | $256K | |
ENDO-156 GLP-1 RA · Type 2 Diabetes maintenance | Eli Lilly Parexel | Endocrinology Phase IV | Active | 100% | $332K | $332K |